Diamyd Medical terminates its phase III trial, Diagnode-3, after interim analysis shows its immunotherapy Diamyd (retogatein) fails to achieve clinically meaningful improvements in C-peptide levels for newly diagnosed type 1 diabetes patients. The company now begins a strategic review following the setback in its key study. The decision stems from the trial not meeting predefined efficacy targets.
Breakthrough T1D develops disease-modifying therapies (DMTs) to alter the progression of type 1 diabetes (T1D). The organization targets slowing, halting, or preventing the disease entirely, alongside reversing it through immune and beta cell therapies. The DIAGNODE-3 study updates progress in these therapeutic approaches.
Diamyd Medical’s independent Data Safety Monitoring Board (DSMB) completes its sixth safety review of the **DIAGNODE-3** trial for its immunotherapy **Diamyd®**, confirming no safety concerns. The trial, evaluating a precision medicine approach for Type 1 Diabetes, proceeds as planned toward an early readout in **March 2026**. The DSMB’s recommendation follows a thorough assessment of interim data.
Diamyd Medical is testing a drug in a clinical trial that aims to protect insulin-producing pancreatic cells from immune attacks in newly diagnosed type 1 diabetes patients. The treatment is administered via injection and targets the underlying autoimmune response. The trial evaluates whether the therapy can preserve residual beta-cell function in affected individuals.
Diamyd Medical’s independent Data Safety Monitoring Board (DSMB) advises continuing the **Phase III DIAGNODE-3 trial** for its **type 1 diabetes (T1D) treatment** without changes. The trial remains unmodified following the DSMB’s review of safety and progress. Diamyd develops therapies targeting autoimmune diseases, including T1D.
Diamyd Medical partners with JDRF to advance a Phase 3 trial of its immunotherapy treatment targeting recently diagnosed type 1 diabetes patients. The four-year research collaboration aims to evaluate the efficacy of Diamyd’s experimental therapy in delaying disease progression. Both organizations emphasize the potential to transform early intervention strategies for T1D.